Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

Bibliographic Details
Main Authors: L. Kaynar, P. Coppo, M. Scully, J. De La Rubia, F. Peyvandi, S. Cataland, J. A. Kremer Hovinga, P. Knoebl, K. Pavenski, J. Minkue Mi Edou, F. Callewaert, R. De Passos Sousa
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920302431
id doaj-86642bdc87514c7db7e170709e05ebc8
record_format Article
spelling doaj-86642bdc87514c7db7e170709e05ebc82020-11-25T03:07:50ZengElsevierHematology, Transfusion and Cell Therapy2531-13792020-10-01426263Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpuraL. Kaynar0P. Coppo1M. Scully2J. De La Rubia3F. Peyvandi4S. Cataland5J. A. Kremer Hovinga6P. Knoebl7K. Pavenski8J. Minkue Mi Edou9F. Callewaert10R. De Passos Sousa11Erciyes University, Kayseri, Turkey; Corresponding author.Saint-Antoine University Hospital, AP-HP, Paris, FranceNational Institute for Health Research UCLH-UCL Biomedical Research Center, London, United KingdomCatholic University of Valencia and Hospital Doctor Peset Valencia, Valencia, SpainUniversità degli Studi di Milano, Milan, ItalyThe Ohio State University, Columbus, OH, United StatesBern University Hospital, University of Bern, Bern, SwitzerlandMedical University of Vienna, Vienna, AustriaSt. Michael's Hospital and University of Toronto, Toronto, ON, CanadaAblynx, a Sanofi Company, Zwijnaarde, BelgiumSanofi, Diegem, BelgiumSanofi, Lisbon, Portugalhttp://www.sciencedirect.com/science/article/pii/S2531137920302431
collection DOAJ
language English
format Article
sources DOAJ
author L. Kaynar
P. Coppo
M. Scully
J. De La Rubia
F. Peyvandi
S. Cataland
J. A. Kremer Hovinga
P. Knoebl
K. Pavenski
J. Minkue Mi Edou
F. Callewaert
R. De Passos Sousa
spellingShingle L. Kaynar
P. Coppo
M. Scully
J. De La Rubia
F. Peyvandi
S. Cataland
J. A. Kremer Hovinga
P. Knoebl
K. Pavenski
J. Minkue Mi Edou
F. Callewaert
R. De Passos Sousa
Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
Hematology, Transfusion and Cell Therapy
author_facet L. Kaynar
P. Coppo
M. Scully
J. De La Rubia
F. Peyvandi
S. Cataland
J. A. Kremer Hovinga
P. Knoebl
K. Pavenski
J. Minkue Mi Edou
F. Callewaert
R. De Passos Sousa
author_sort L. Kaynar
title Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
title_short Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
title_full Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
title_fullStr Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
title_full_unstemmed Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
title_sort caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
publisher Elsevier
series Hematology, Transfusion and Cell Therapy
issn 2531-1379
publishDate 2020-10-01
url http://www.sciencedirect.com/science/article/pii/S2531137920302431
work_keys_str_mv AT lkaynar caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT pcoppo caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT mscully caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT jdelarubia caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT fpeyvandi caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT scataland caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT jakremerhovinga caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT pknoebl caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT kpavenski caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT jminkuemiedou caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT fcallewaert caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
AT rdepassossousa caplacizumabinducesfastanddurableplateletcountresponseswithimprovedtimetocompleteremissionandrecurrencefreesurvivalinpatientswithacquiredthromboticthrombocytopenicpurpura
_version_ 1724668822229614592

Similar Items